Veracyte, Inc. (VCYT): Bonnie H Anderson , CEO of Veracyte, Inc. purchased 5,000 shares on Jun 2, 2016. The Insider buying transaction was reported by the company on Jun 3, 2016 to the Securities and Exchange Commission. The shares were purchased at $5.40 per share for a total value of $26,981.25 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Jun 1, 2016, Bonnie H Anderson (CEO) purchased 5,000 shares at $5.46 per share price.On Nov 25, 2015, Evan/ Fa Jones (director) sold 15,000 shares at $7.22 per share price.Also, On Jul 28, 2015, Shelly D Guyer (Chief Financial Officer) sold 1,000 shares at $12.47 per share price.On Jul 23, 2015, Christopher M Hall (Chief Operating Officer) sold 2,500 shares at $11.85 per share price.
Shares of Veracyte Inc (VCYT) ended Friday, Jun 3, 2016 session in red amid volatile trading. The shares closed down -0.18 points or -3.28% at $5.3 with 68,219 shares getting traded. Post opening the session at $5.5, the shares hit an intraday low of $5.25 and an intraday high of $5.5 and the price vacillated in this range throughout the day. The company has a market cap of $148 M and the number of outstanding shares has been calculated to be 2,78,58,317 shares. The 52-week high of Veracyte Inc is $12.47 and the 52-week low is $4.21.
Veracyte Inc. is a molecular diagnostics company. The Company is engaged in the field of molecular cytology providing genomic solutions to resolve diagnostic ambiguity and enable physicians to make treatment decisions at an early stage in patient care. It targets diseases in which a large number of patients undergo invasive diagnostic procedures that could be avoided with a diagnosis from a cytology sample. The Company’s commercial solution the Afirma Thyroid FNA Analysis includes as its centerpiece the Gene Expression Classifier (GEC). The GEC allows physicians reduce the number of surgeries by employing a 142-gene signature to pre-operatively determine whether thyroid nodules previously classified by cytopathology as indeterminate can be reclassified as benign. The offering also includes cytopathology testing and the Afirma Malignancy Classifiers. The Company markets and sells Afrma through a co-promotion agreement with Genzyme Corporation a subsidiary of Sanofi.